Pfiz­er bankrolls an on­colyt­ics biotech up­start with an eye on a fu­ture buy­out

Pfiz­er is bankrolling a new on­colyt­ic virus start­up, tak­ing a 50% stake in the can­cer drug out­fit while hold­ing an op­tion to buy it if the founders ap­pear to be on the right R&D track.

The up­start is Ig­nite Im­munother­a­py, based in Alame­da, CA, which is be­ing launched by a group of ex­pe­ri­enced on­colyt­ics hands. Berke­ley ad­junct pro­fes­sor David Kirn, the CEO of 4D Mol­e­c­u­lar Ther­a­peu­tics, is the co-founder, along with Berke­ley’s Dave Schaf­fer.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.